Navigation Links
Bionovo Announces Closing of Public Offering of Common Stock
Date:10/31/2007

EMERYVILLE, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a leader in the discovery and development of safe and effective drugs in the areas of women's health and cancer, announced today that it has completed the previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $2.50 per share and 5,000,000 warrants to purchase shares of common stock at $3.50 per share at a price of $0.10 per warrant. The net proceeds to the company of the offering were approximately $24.0 million, after payment of underwriting discounts and commissions, but excluding estimated offering expenses. Bionovo will use the proceeds to advance its clinical programs.

Bionovo has granted the underwriters a 30-day option to purchase up to an additional 15% of the offering to cover over-allotments. All of the shares were offered by Bionovo. BMO Capital Markets Corp. and Canaccord Adams Inc. acted as joint book-running managers for the offering, with Merriman Curhan Ford & Co. (Amex: MEM) acting as a co-manager.

Isaac Cohen, Chairman and CEO of Bionovo, said, "We're pleased to have the funding to progress our clinical programs, as we strive to bring to market safe and effective therapeutics for currently unmet needs in women's health. It is unfortunate that, despite new innovations like Bionovo's, there are many women's health issues that receive insufficient attention."

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus may be obtained from: BMO Capital Markets Corp., Attn: Prospectus Delivery Department, 3 Times Square, New York, New York 10036; Telephone: (212) 702-1969. A prospectus supplement relating to the offering has been filed with the SEC, and is available along with the base prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at http://www.sec.gov/.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... a one-day corporate governance program for mid-market executives as a kick-off to the ... held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, followed by ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... insurance management and financial planning assistance to clients in southern Montana, is announcing ... offered by Zoo Montana. , The outreach programs offered by Zoo Montana provide ...
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, ... Finnegan to the position of Executive Vice President, Sales and Marketing. Finnegan is ... telehealth and medical device sales leadership. He has received industry recognition for innovations ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... solution for many of the health care industry’s hospitals and provider groups, has ... financing portal for select customers. Parasail Health is a San Francisco health-finance startup ...
(Date:6/27/2017)... ... 27, 2017 , ... A January 18th article on medGadget reports ... billion by the year 2024 according to a new report. The article also notes ... from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 /PRNewswire/ ... diabetes. In a further effort to help spread lessons ... this condition, the International Diabetes Federation (IDF) and Eli ... come together for the second phase of the Bringing ... (BRIDGES 2), reaffirming their commitment to helping people with ...
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
(Date:6/7/2017)... , June 6, 2017  Diplomat Specialty Infusion Group, a brand ... environment to its Iowa location. ... now features an ISO 7 cleanroom—the standard needed to ... with a low level of pollutants. ... nutrition consumers and better serve our Iowa ...
Breaking Medicine Technology: